Reply to thread

plus the pipeline drug pela something sucks compared to VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1.. it was just added monotherapy to NCCN guidelines as first line monotherapy. this company's drug has to be used in combination to get results. there are no cytopenias with VONJO but there are with JAK2 inhibitors